QNRX 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-14

• On June 2, 2026, we submitted our IND application for QRX003 in Peeling Skin Syndrome to the FDA and IND clearance to initiate a Phase 2 study of QRX003 in Peeling Skin Syndrome was received from the FDA on July 9, 2026.

• On June 16, 2026, we provided a clinical update from our ongoing pediatric Netherton Syndrome compassionate use program. Four of six patients participating in the program were classified as “improved” or “significantly improved” from baseline assessment across key clinical endpoints. All six patient…

• On June 23, 2026, we received conditional FDA approval of QYLEKI as the proposed brand name for QRX003 for Netherton Syndrome.

• Results of Operations – Six months ended June 30, 2026 compared to the six months ended June 30, 2025

• The following table sets forth our results of operations for the six months ended June 30, 2026, compared to the six months ended June 30, 2025:

相对上期删除的文字 · 来源:10-Q · 2026-05-07

• We have incurred net losses every year since inception and had an accumulated deficit of approximately $76.0 million at March 31, 2026. We have a limited operating history and have historically funded our operations through our founders’ funding expenditures and debt and equity financings. We incurr…

• Net cash provided by financing activities was approximately $56,000 for the three months ended March 31, 2026. The net cash provided increased due to the receipt of approximately $206,000 in net proceeds from the exercise of warrants, partially offset by repayments of amounts due to officers of $150…